Studies recruiting patients with FSGS
Phase 2/3 Adaptive Study of VX-147 in Adults With APOL1- Mediated Proteinuric Kidney Disease
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-147 in high risk APOL1 genotypes and proteinuric kidney disease.
Site PI: Dr. Afolarin Amodu
Contact: Afolarin.Amodu@bmc.org
​Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
Site PI: Dr. Lesley Inker
Contact: lesley.inker@tuftsmedicine.org
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Site PI: Dr. Lesley Inker
Contact: lesley.inker@tuftsmedicine.org
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (AMPLITUDE)
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Site PI: Dr. Daniel Weiner
Contact: daniel.weiner@tuftsmedicine.org